Please assess the completion status of the following clinical trial:

Trial Title: Paracetamol Effect on Oxidative Stress and Renal Function in Severe Malaria

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Patient age \>12 years~2. Presence of severe or moderately severe P. falciparum malaria, with and without blackwater fever, confirmed by positive blood smear with asexual forms of P. falciparum~3. Temperature \>38 degrees Celsius on admission or fever during the preceding 24hours~4. Written informed consent from patient or attending relative able to and willing to give informed consent. Consent form and information sheets will be translated into Bangla and copies provided to the patient.~Exclusion Criteria:~1. Patient or relatives unable or unwilling to give informed consent~2. History of chronic liver disease~3. History of alcohol use (\>3drinks per day)~4. Contraindication or allergy to paracetamol or artesunate therapy~5. Contraindication to nasogastric tube insertion i.e. facial fracture, bleeding diathesis~6. Pregnancy

- Gender: ALL
- Minimum Age: 12 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Paracetamol (Type: EXPERIMENTAL): \>50kg: Paracetamol 1gm PO/NG q6hourly for 72 hours and febrile for 24 hours (maximum total dose 4g/24 hours) plus intravenous Artesunate~\<50kg: Paracetamol 12.5-15mg/kg/dose q6hourly for 72 hours and febrile for 24 hours (maximum total dose 5 doses/24hours;75mg/kg) plus intravenous Artesunate
- No Paracetamol (Type: ACTIVE_COMPARATOR): No paracetamol + Intravenous Artesunate~* If temperature \> 40°C, ibuprofen PO/PR will be administered in the absence of renal impairment and dehydration; 500mg paracetamol PO/PR will be administered in the presence of renal impairment or dehydration. Dengue testing will be done prior to the administration of ibuprofen.

Based on this trial design, predict the completion outcome and termination type (if applicable).